---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-173010"
form_type: "8-K"
ticker: "STTK"
cik: "0001680367"
company_name: "Shattuck Labs, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:48:08.696703+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials

## Summary
- Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
- OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.
- Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.
- Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.
- Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing.

## SEC filing metadata
- accession: 0001193125-25-173010
- form_type: 8-K
- ticker: STTK
- cik: 0001680367
- company_name: Shattuck Labs, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/0001193125-25-173010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/d12427d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-173010
- JSON: https://secwatch.observer/filing/0001193125-25-173010.json
- Plain text: https://secwatch.observer/filing/0001193125-25-173010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.